TAU V337M

The tau protein normally helps stabilize the cellular skeleton in neurons, but mutations can cause it to misfold and aggregate into toxic clumps called neurofibrillary tangles. The P301L mutation, where proline at position 301 is replaced by leucine, is classified as pathogenic by ClinVar based on criteria from multiple expert submitters with no conflicts, and has not been observed in the gnomAD population database—a strong indicator that it causes disease rather than representing normal human variation. This mutation occurs in frontotemporal dementia families and is extensively studied as a model for understanding tau dysfunction in Alzheimer's disease. The current AlphaFold2 structural prediction achieved an average confidence score (pLDDT) of 55.1, which falls well below the 70-point threshold typically considered reliable for structural interpretation. This low confidence reflects an inherent challenge: tau is an intrinsically disordered protein that lacks a stable three-dimensional structure in its normal state, making it difficult for computational methods to predict its conformation accurately. The substantial structural uncertainty means that specific atomic-level details from this prediction should be interpreted with caution and cannot be directly compared to experimental structures without independent validation. Despite limitations in predicting tau's disordered structure computationally, extensive experimental research has established how P301L drives disease. The mutation accelerates tau's conversion from its normal disordered state into rigid, fibrous aggregates that template the spread of pathology throughout the brain in a prion-like manner [4]. Studies show that P301L specifically promotes formation of four-repeat (4R) tau fibrils with distinctive strand-loop-strand structural motifs, lowers the energy barrier for aggregation-prone conformations, and increases the rate at which new aggregates form compared to normal tau [1]. The mutation also severely impairs the cell's ability to clear damaged tau through multiple degradation pathways, including chaperone-mediated autophagy and macroautophagy, allowing toxic protein to accumulate [2]. Beyond aggregation, P301L disrupts normal cellular function through multiple mechanisms. It weakens tau's ability to bind and stabilize microtubules—the cellular railways that transport materials within neurons—accelerating formation of pathological tangles [5]. The mutation also inappropriately activates the mTOR signaling pathway, boosting overall protein production in neurons and potentially overwhelming the cell's quality control systems [3]. When combined with phosphorylation modifications that normally regulate tau, P301L potentiates stress responses, microtubule disruption, and the ability of aggregates to recruit normal tau into growing tangles [6]. The pathogenic classification and absence from healthy populations underscore P301L's role as a direct cause of neurodegeneration in carriers. While the current structural prediction's low confidence prevents detailed atomic-level insights, the mutation's established effects on aggregation kinetics, cellular clearance mechanisms, and microtubule dynamics explain how a single amino acid change triggers the devastating neuronal loss characteristic of frontotemporal dementia and provides crucial insights into sporadic Alzheimer's disease pathology.